Literature DB >> 3625401

Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease.

T W Chin, E R Stiehm, J Falloon, J I Gallin.   

Abstract

Two patients with chronic granulomatous disease had obstructive lesions of the gastrointestinal tract, esophagus, and genitourinary tract, which were successfully treated with corticosteroids. These obstructive lesions, caused by local granuloma formation, have been reported in 18 other patients with chronic granulomatous disease, none of whom received steroids. Our first patient, a 3-year-old boy, had emesis and weight loss associated with antral narrowing and delayed gastric emptying at age 2 years. Antibiotic therapy was ineffective, but intravenous and oral corticosteroid therapy for 10 weeks resulted in clinical cure. One year later, dysuria associated with bladder neck obstruction was also treated successfully with corticosteroids. The second child, a 10-year-old boy, had dysphagia caused by distal esophageal stenosis. Corticosteroid therapy (with concomitant antibiotics) on two occasions reversed this obstruction. Granulomatous cystitis with ureteropelvic obstruction then developed, which also responded to treatment with corticosteroids and antibiotics. Despite the risk of increased susceptibility to infection, corticosteroid therapy is justified in preventing life-threatening obstruction of vital organs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3625401     DOI: 10.1016/s0022-3476(87)80452-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  25 in total

Review 1.  Chronic granulomatous disease.

Authors:  D Goldblatt; A J Thrasher
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

Review 2.  Neutrophil disorders and their management.

Authors:  R Lakshman; A Finn
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

3.  Scedosporium apiospermum in chronic granulomatous disease treated with an HLA matched bone marrow transplant.

Authors:  M M Gompels; C A Bethune; G Jackson; G P Spickett
Journal:  J Clin Pathol       Date:  2002-10       Impact factor: 3.411

4.  Colitis in chronic granulomatous disease.

Authors:  M G Schäppi; V V Smith; D Goldblatt; K J Lindley; P J Milla
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

5.  Polymorphonuclear leucocytes selectively produce anti-inflammatory interleukin-1 receptor antagonist and chemokines, but fail to produce pro-inflammatory mediators.

Authors:  Anja K Schröder; Maren von der Ohe; Ute Kolling; Julia Altstaedt; Peter Uciechowski; Daniela Fleischer; Klaus Dalhoff; Xinsheng Ju; Martin Zenke; Nicole Heussen; Lothar Rink
Journal:  Immunology       Date:  2006-11       Impact factor: 7.397

Review 6.  Chronic granulomatous disease.

Authors:  Dirk Roos
Journal:  Br Med Bull       Date:  2016-03-16       Impact factor: 4.291

7.  Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: cell fate is regulated at the level of gene expression.

Authors:  Scott D Kobayashi; Jovanka M Voyich; Cassandra L Buhl; Robert M Stahl; Frank R DeLeo
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

8.  Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species.

Authors:  Marina D Kraaij; Nigel D L Savage; Sandra W van der Kooij; Karin Koekkoek; Jun Wang; J Merlijn van den Berg; Tom H M Ottenhoff; Taco W Kuijpers; Rikard Holmdahl; Cees van Kooten; Kyra A Gelderman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-22       Impact factor: 11.205

Review 9.  The molecular basis of chronic granulomatous disease.

Authors:  C Meischl; D Roos
Journal:  Springer Semin Immunopathol       Date:  1998

10.  Host defense molecule polymorphisms influence the risk for immune-mediated complications in chronic granulomatous disease.

Authors:  C B Foster; T Lehrnbecher; F Mol; S M Steinberg; D J Venzon; T J Walsh; D Noack; J Rae; J A Winkelstein; J T Curnutte; S J Chanock
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.